CNCE earnings call for the period ending June 30,2019.
News & Analysis: Concert Pharmaceuticals
CNCE earnings call for the period ending March 31, 2019.
CNCE earnings call for the period ending December 31, 2018.
Bad news trumps good news for the biotech.
Even on a quiet day on Wall Street, these stocks posted gains. Find out why.
Why Spark Therapeutics, Albany Molecular Research, and Concert Pharmaceuticals could be great biotech stocks to buy as spring approaches.
The pharma cut a deal with Vertex for the experimental experimental cystic fibrosis drug CTP-656.
With two new correctors entering clinical development, Vertex is about to leave Galapagos and Concert in the dust.
Concert Pharmaceuticals' phase 1 data dazzles when put side by side with a major competitors' FDA-approved cystic fibrosis drug,
Concert shares get blasted in Thursday's trading session after announcing a common stock offering. Find out why this is both good and bad news for current shareholders.